## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF MATHES ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/11034

Express Mail Label Number

FILED: 6 OCTOBER 2005

U.S. APPLICATION NO: Not Yet Assigned

35 USC §371 DATE:

FOR: ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH

ENANTIOMERS OF 10, 11-DIHYDRO-10-HYDROXY-5H-

DIBENZ[B,F]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS

THEREOF

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## **INFORMATION DISCLOSURE STATEMENT**

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/11034, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis
Corporate Intellectual Property
One Health Bloom Building 104

One Health Plaza, Building 104 East Hanover, NJ 07936-1080

(862) 778-7960 Date: April 7, 2005 Respectfully submitted,

Edward J. Wlusz, Jr. Attorney for Applicants

Reg. No. 52,370

FORM PTO-1449 PEPARTMENT OF COMMERCE (REV. 7-85) TAND TRADEMARK OFFICE INFORMATION DISSESSIBLE CITATION

(Use several sheets if necessary)

JCATTON POT POT POT POT POT APPLICATION NO.
Not Yet Assigned APPLICANT

MATHES ET AL. FILING DATE

Group

## **U.S. PATENT DOCUMENTS EXAMINER DOCUMENT NUMBER** DATE NAME CLASS **SUBCLASS FILING DATE** INITIAL AA AB AC AD ΑE AF AG AH ΑI AJ AK AL **FOREIGN PATENT DOCUMENTS** TRANSLATION YES NO **DOCUMENT NUMBER** DATE OFFICE **CLASS SUBCLASS WIPO** AM WO 00 76942 12/21/00 AN AO AP AQ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) MOHAR, BARBARA ET AL: "Highly enantioselective synthesis via dynamic kinetic resolution under AR transfer hydrogenation using Ru(.eta.6- arene)-N-perfluorosulfonyl-1,2-diamine catalysts: a first insight into the relationship of the ligand's pKa and the catalyst activity" Chemical Communications (Cambridge, United Kingdom) (2001), (24), 2572-2573, XP002270702 TARAN F ET AL: "High-Throughput Screening Of Enantioselective Catalysts By Immunoassay" Angewandte Chemie. International Edition, Verlag Chemie. Weinheim, DE, vol. 41, no. 1, 4 January AS 2002 (2002-01-04), pages 124-127, XP001102322 ISSN: 0570-0833 BENES J ET AL: "Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5H-dibenzÄb,fuazepine-5-carb oxamide Derivatives" Journal Of Medicinal Chemistry, American AT Chemical Society. Washington, US, vol. 42, 1999, pages 2582-2587, XP002206156 ISSN: 0022-2623 **EXAMINER DATE CONSIDERED**



JC13 Recid PCT/PTO 7. APR 2005

ATTY. IT NO PN/4-323A APPLICATION NO. Not Yet Assigned APPLICANT MATHES ET AL. FILING DATE

10/530617

Group

EXAMINER INITIAL	ОТН	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)	
	DA	HAACK K J ET AL: "The catalyst precursor, catalyst and intermediate in the Rull-promoted asymmetric hydrogen transfer between alcohols and ketones "Angewandte Chemie. International Edition, Verlag Chemie. Weinheim, DE,vol. 36, no. 3, 1997, pages 285-288, XP002092423 ISSN: 0570-0833	
	DB	LISGARTEN, JOHN N. ET AL: "The structure of 10,11-dihydro-10-hydroxy-5H-dibenzÄb,fÜaze pine-5- carboxamide, an anticonvulsant drug molecule" Acta Crystallographica, Section C: Crystal Structure Communications (1989), C45(4), 656-8, XP008027747	
	DC		
	DD		
	DE		
	DF		
	DG		
	DH		
	DI		
	DJ		
	DK		
	DL		
	DM		
	DN		
EXAMINE	R	DATE CONSIDERED	

<sup>\*</sup>EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.